Cell therapies with the potential to save lives.

A focused pipeline of late-stage assets.

A focused pipeline of late-stage assets.

Redefining cancer treatment demands a robust and focused pipeline paving the way for successful outcomes.

Our engineered T-cell therapies offer specificity and are administered with a single-dose delivery. We are guided 
by rigorous scientific principles and a strategically focused development pipeline that prioritizes late-stage assets like afami-cel and lete-cel.

Our Clinical Pipeline

Adaptimmune is developing an industry-leading T-cell therapy pipeline in solid tumors and has a deep pipeline of identified and proprietary targets for further product development.

Program [Target] Trial Name(s) / Indications / Design Ind-Enabling Phase 1 Phase 2/3 Registration
afami-cel [MAGE-A4] SPEARHEAD-1 pivotal trial Synovial sarcoma
Ind-Enabling complete
Phase 1 complete
Phase 2/3 complete
Registration in progress
lete-cel [NY-ESO] IGNYTE-ESO Synovial sarcoma and MRCLS
Ind-Enabling complete
Phase 1 complete
Phase 2/3 in progress
Registration not started
uza-cel
(ADP-A2M4CD8*) [MAGE-A4]
SURPASS-3 registration-directed trial Platinum resistant ovarian cancer; Monotherapy; +/- checkpoint inhibitor
Ind-Enabling complete
Phase 1 complete
Phase 2/3 in progress
Registration not started
uza-cel
(ADP-A2M4CD8*) [MAGE-A4]
SURPASS Ph 1 Head & neck cancer Focus on earlier line therapy +/- checkpoint inhibitor
Ind-Enabling complete
Phase 1 in progress
Phase 2/3 not started
Registration not started
uza-cel
(ADP-A2M4CD8*) [MAGE-A4]
SURPASS ph1 urothelial cancer Focus on earlier line therapy +/- checkpoint inhibitor
Ind-Enabling complete
Phase 1 in progress
Phase 2/3 not started
Registration not started
ADP-600 [PRAME] Indications that express PRAME including synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian and head & neck cancers. Clinical Indications TBD
Ind-Enabling in progress
Phase 1 not started
Phase 2/3 not started
Registration not started
ADP-520 [CD70] Indications that express CD70 including hematological, malignancies, acute myeloid leukemia (AML), lymphoma and renal cell carcinoma (RCC). Clinical Indications TBD
Ind-Enabling in progress
Phase 1 not started
Phase 2/3 not started
Registration not started

* SURPASS Ph 1 no longer enrolling for indications other than head & neck and urothelial cancers

Promising preclinical allogeneic therapies

We have built one of the leading allogeneic T-cell platforms using human-induced pluripotent stem cell lines (hlPSCs). This platform is flexible and produces functional T-cells that kill tumor cells in vitro. We will combine this platform with everything we have learned from decades of autologous T-cell therapy research and development into a pipeline for Adaptimmune and its partners for off-the-shelf cell or allogeneic T-cell therapies.

Allogeneic Preclinical
Program [Target] Trial Name(s) / Indications / Design Discovery Ind-Enabling Phase 1 Phase 2/3 Registration
Off-the-shelf TCR therapy target 1 TBA
Discovery in progress
Ind-Enabling not started
Phase 1 not started
Phase 2/3 not started
Registration not started
Personalized cell therapy platform TBA
Discovery in progress
Ind-Enabling not started
Phase 1 not started
Phase 2/3 not started
Registration not started